1. Home
  2. AG vs COGT Comparison

AG vs COGT Comparison

Compare AG & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Majestic Silver Corp. (Canada)

AG

First Majestic Silver Corp. (Canada)

HOLD

Current Price

$16.19

Market Cap

5.9B

ML Signal

HOLD

Logo Cogent Biosciences Inc.

COGT

Cogent Biosciences Inc.

HOLD

Current Price

$37.63

Market Cap

6.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AG
COGT
Founded
1979
2014
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9B
6.5B
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
AG
COGT
Price
$16.19
$37.63
Analyst Decision
Strong Buy
Buy
Analyst Count
3
13
Target Price
$14.25
$28.08
AVG Volume (30 Days)
19.8M
2.8M
Earning Date
11-05-2025
11-03-2025
Dividend Yield
0.13%
N/A
EPS Growth
N/A
N/A
EPS
0.16
N/A
Revenue
$965,571,000.00
N/A
Revenue This Year
$107.63
N/A
Revenue Next Year
$18.81
N/A
P/E Ratio
$102.20
N/A
Revenue Growth
83.84
N/A
52 Week Low
$5.09
$3.72
52 Week High
$17.37
$43.73

Technical Indicators

Market Signals
Indicator
AG
COGT
Relative Strength Index (RSI) 62.95 56.58
Support Level $15.68 $37.86
Resistance Level $17.00 $42.25
Average True Range (ATR) 0.93 2.20
MACD 0.09 -0.90
Stochastic Oscillator 61.80 6.84

Price Performance

Historical Comparison
AG
COGT

About AG First Majestic Silver Corp. (Canada)

First Majestic Silver Corp is engaged in the production, development, exploration, and acquisition of mineral properties with a focus on silver and gold production in North America. It owns three producing mines in Mexico consisting of the San Dimas Silver/Gold Mine, the Santa Elena Silver/Gold Mine, and the La Encantada Silver Mine.

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Share on Social Networks: